Takeshi Imaoka

1.4k total citations · 1 hit paper
50 papers, 1.2k citations indexed

About

Takeshi Imaoka is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Takeshi Imaoka has authored 50 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Endocrinology, Diabetes and Metabolism, 15 papers in Molecular Biology and 9 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Takeshi Imaoka's work include Diabetes Treatment and Management (21 papers), Diabetes Management and Research (17 papers) and Metabolism, Diabetes, and Cancer (12 papers). Takeshi Imaoka is often cited by papers focused on Diabetes Treatment and Management (21 papers), Diabetes Management and Research (17 papers) and Metabolism, Diabetes, and Cancer (12 papers). Takeshi Imaoka collaborates with scholars based in Japan, United States and Spain. Takeshi Imaoka's co-authors include Tomonori Oura, Masakazu Takeuchi, Nobuya Inagaki, Yutaka Seino, Takashi Kadowaki, Akichika Ozeki, Masato Odawara, Jun‐ichiro Miyagawa, Noriyuki Iwamoto and Toshinari Takamura and has published in prestigious journals such as Journal of the American College of Cardiology, Diabetes and American Journal of Physiology-Heart and Circulatory Physiology.

In The Last Decade

Takeshi Imaoka

50 papers receiving 1.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy and safety of tirzepatide monotherapy compared with dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono): a double-blind, multicentre, randomised, phase 3 trial

2022 145 citations Masakazu Takeuchi, Tomonori Oura et al. The Lancet Diabetes & Endocrinology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Takeshi Imaoka Japan	19	809	457	249	220	106	50	1.2k
Everton Rowe United States	12	731 0.9×	386 0.8×	199 0.8×	567 2.6×	31 0.3×	26	1.2k
Michael Croxson New Zealand	20	658 0.8×	187 0.4×	262 1.1×	18 0.1×	16 0.2×	58	1.2k
P. Liss Sweden	13	157 0.2×	191 0.4×	271 1.1×	66 0.3×	22 0.2×	18	955
Donald L. Akers United States	14	126 0.2×	110 0.2×	236 0.9×	42 0.2×	35 0.3×	33	766
Christina Köhler Germany	15	160 0.2×	142 0.3×	298 1.2×	68 0.3×	18 0.2×	33	1.3k
Shinichiro Ueda Japan	13	139 0.2×	83 0.2×	98 0.4×	40 0.2×	31 0.3×	50	568
Mara Fallarino Italy	14	141 0.2×	120 0.3×	133 0.5×	29 0.1×	15 0.1×	20	562
M. C. DELAUCHE‐CAVALLIER France	9	263 0.3×	51 0.1×	158 0.6×	144 0.7×	477 4.5×	10	694
Robert Haws United States	15	136 0.2×	331 0.7×	116 0.5×	63 0.3×	33 0.3×	33	785
Anna Mitchell Germany	15	139 0.2×	122 0.3×	160 0.6×	42 0.2×	11 0.1×	42	972

Countries citing papers authored by Takeshi Imaoka

Since Specialization

Citations

This map shows the geographic impact of Takeshi Imaoka's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Takeshi Imaoka with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Takeshi Imaoka more than expected).

Fields of papers citing papers by Takeshi Imaoka

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Takeshi Imaoka. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Takeshi Imaoka. The network helps show where Takeshi Imaoka may publish in the future.

Co-authorship network of co-authors of Takeshi Imaoka

This figure shows the co-authorship network connecting the top 25 collaborators of Takeshi Imaoka. A scholar is included among the top collaborators of Takeshi Imaoka based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Takeshi Imaoka. Takeshi Imaoka is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kadowaki, Takashi, et al.. (2022). Safety and efficacy of tirzepatide as an add-on to single oral antihyperglycaemic medication in patients with type 2 diabetes in Japan (SURPASS J-combo): a multicentre, randomised, open-label, parallel-group, phase 3 trial. The Lancet Diabetes & Endocrinology. 10(9). 634–644. 93 indexed citations

Dunn, Julia P., et al.. (2022). Safety and efficacy analyses across age and body mass index subgroups in East Asian participants with type 2 diabetes in the phase 3 tirzepatide studies ( SURPASS programme). Diabetes Obesity and Metabolism. 25(4). 1056–1067. 18 indexed citations

Furihata, Kenichi, et al.. (2021). A phase 1 multiple‐ascending dose study of tirzepatide in Japanese participants with type 2 diabetes. Diabetes Obesity and Metabolism. 24(2). 239–246. 50 indexed citations

Taki, Kentaro, et al.. (2020). Long-term safety and effectiveness of biosimilar insulin glargine in Japanese patients with diabetes mellitus in routine clinical practice: results of a post-marketing safety study. Current Medical Research and Opinion. 36(6). 947–958. 8 indexed citations

Miura, Junnosuke, et al.. (2020). Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients with Type 1 Diabetes: PRONTO-T1D Subpopulation Analysis. Diabetes Therapy. 11(9). 2089–2104. 7 indexed citations

Jinnouchi, Hideaki, et al.. (2020). Ultra-Rapid Lispro Efficacy and Safety Compared to Humalog® in Japanese Patients With Type 2 Diabetes: PRONTO-T2D Subpopulation Analysis. Diabetes Therapy. 11(9). 2075–2088. 2 indexed citations

Miyagawa, Jun‐ichiro, et al.. (2015). Once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide is non‐inferior to once‐daily liraglutide and superior to placebo in J apanese patients with type 2 diabetes: a 26‐week randomized phase III study. Diabetes Obesity and Metabolism. 17(10). 974–983. 82 indexed citations

Ishii, Hitoshi, Yasuo Terauchi, Hideaki Jinnouchi, et al.. (2013). Effects of insulin changes on quality of life and glycemic control in Japanese patients with type 2 diabetes mellitus: The insulin‐changing study intending to gain patients' insights into insulin treatment with patient‐reported health outcomes in actual clinical treatments (INSIGHTs) study. Journal of Diabetes Investigation. 4(6). 560–570. 12 indexed citations

Onishi, Yukiko, Hiroyuki Koshiyama, Takeshi Imaoka, et al.. (2012). Safety of exenatide once weekly for 52 weeks in Japanese patients with type 2 diabetes mellitus. Journal of Diabetes Investigation. 4(2). 182–189. 11 indexed citations

10.

Iribe, Gentaro, Juichiro Shimizu, Satoshi Mohri, et al.. (2004). Arterial and Left Ventricular Pressures Illude Transient Alternans of Contractility during Postextrasystolic Potentiation. The Japanese Journal of Physiology. 54(4). 373–383. 1 indexed citations

11.

Nakai, Satoru, Tsuyoshi Hirose, Yasufumi Uwahodo, et al.. (2003). Diminished catalepsy and dopamine metabolism distinguish aripiprazole from haloperidol or risperidone. European Journal of Pharmacology. 472(1-2). 89–97. 39 indexed citations

12.

Kiyooka, Takahiko, Gentaro Iribe, Juichiro Shimizu, et al.. (2002). EFFECTS OF HEART RATE ON EXCITATION-CONTRACTION COUPLING ENERGETICS IN CANINE LEFT VENTRICLE. Japanese Circulation Journal-english Edition. 66. 441. 1 indexed citations

13.

Shimizu, Juichiro, Junichi Araki, Gentaro Iribe, et al.. (2000). Postextrasystolic contractile decay always contains exponential and alternans components in canine heart. American Journal of Physiology-Heart and Circulatory Physiology. 279(1). H225–H233. 18 indexed citations

14.

Mizuno, Ju, Junichi Araki, Gentaro Iribe, et al.. (1999). Total Ca handling in canine mild Ca overload failing heart. Heart and Vessels. 14(1). 38–51. 9 indexed citations

15.

Mohri, Satoshi, Junichi Araki, Takeshi Imaoka, et al.. (1999). Myocardial mechanical restitution and potentiation partly underlie alternans decay of postextrasystolic potentiation: Simulation. Heart and Vessels. 14(2). 82–89. 8 indexed citations

16.

Iwabuchi, Masashi, et al.. (1997). Intravascular Ultrasound Findings After Successful Primary Angioplasty for Acute Myocardial Infarction: Predictors of Abrupt Occlusion. Journal of the American College of Cardiology. 30(6). 1437–1444. 8 indexed citations

17.

Iwabuchi, Masashi, et al.. (1996). Intravascular ultrasound after primary angloplasty for acute myocardial infarction: Predictors of acute coronary occulusion. Journal of the American College of Cardiology. 27(2). 198–198. 1 indexed citations

18.

Imaoka, Takeshi, et al.. (1996). Leukopenia-Inducing Effect of a Combination of a New 5-Fluorouracil (5-FU)-Derived Drug, BOF-A2 (Emitefur), with Other 5-FU-Derived Drugs or BV-araU (Sorivudine) in Rats. The Japanese Journal of Pharmacology. 70(2). 139–148. 5 indexed citations

19.

Imaoka, Takeshi, et al.. (1994). Oral Administration of BOF‐A2 to Rats with Lung Transplanted Tumors Results in Increased 5‐Fluorouracil Levels. Japanese Journal of Cancer Research. 85(6). 665–668. 6 indexed citations

20.

Fujii, Setsuro, Masakazu Fukushima, Yuji Shimamoto, et al.. (1989). Antitumor Activity of BOF‐A2, a New 5‐Fluorouracil Derivative. Japanese Journal of Cancer Research. 80(2). 173–181. 23 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact